EMA’s mCombriax Vaccine Recommendation

By HEOR Staff Writer

March 3, 2026

EMA's mCombriax Vaccine Recommendation Ushers in Dual Protection Era The mCombriax vaccine recommendation from the European Medicines Agency (EMA) marks a milestone...
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025
FDA Guidance on Overall Survival Assessment in Oncology Trials
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical ...
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron ...